Yes, the next Alzheimer’s treatment could indeed come from UNC Pembroke. Dr. Ben Bahr’s Alzheimer’s Disease Research Lab at the university has developed a novel treatment approach using American ginseng as a key ingredient, with research already published in January 2026 in *Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association*. The team is currently conducting preclinical testing on mice with the same genetic mutations that cause Alzheimer’s in humans, moving through FDA-required protocols toward human clinical trials. This article explores what makes this research significant, how it works, where it stands in development, and what timeline patients and families might realistically expect.
The research represents more than academic interest. Dr. Bahr’s lab has already patented Alzheimer’s-related technology (2022) with a second patent pending, developed multiple small-molecule drug candidates that activate protective pathways in the brain, and received NCInnovation Grant funding to accelerate development. Dr. Bahr is launching a spin-off company specifically to commercialize the intellectual property and partner with pharmaceutical companies. This combination of published science, patent protection, government funding, and commercial development suggests this isn’t speculative—it’s a research program actively moving toward real-world application.
Table of Contents
- What is UNC Pembroke’s Breakthrough Approach to Alzheimer’s Treatment?
- How Far Along Is the Research, and What Do the Animal Studies Show?
- What Role Do Patents and Intellectual Property Play in This Development?
- What Does the NCInnovation Grant Mean for Development Timeline?
- What Are the Limitations and Uncertainties in This Research?
- How Does American Ginseng Compare to Other Alzheimer’s Research Approaches?
- What Does This Research Mean for the Future of Alzheimer’s Treatment?
- Conclusion
What is UNC Pembroke’s Breakthrough Approach to Alzheimer’s Treatment?
UNC Pembroke’s approach centers on using American ginseng extract combined with small-molecule drug candidates to address a specific mechanism of cognitive decline. Rather than targeting amyloid plaques or tau tangles—the traditional Alzheimer’s focus—the lab’s research targets synaptic resiliency, which refers to the brain’s ability to maintain and repair the connections between neurons that are essential for memory and thinking. The January 2026 publication in *Alzheimer’s & Dementia* was titled “Ginseng extract improves synaptic resiliency: A key factor for healthy cognitive aging,” indicating that their mechanism of action centers on strengthening these neural connections rather than clearing protein accumulation.
What distinguishes this approach is its potential cost-effectiveness compared to other Alzheimer’s treatments in development. Many experimental Alzheimer’s drugs require expensive biologics manufacturing and infusion protocols. American ginseng is a well-established botanical ingredient with existing supply chains, potentially making a ginseng-based treatment more affordable to manufacture and administer than alternatives. However, botanical efficacy in mice doesn’t automatically translate to humans—the gap between preclinical animal studies and clinical trial success remains substantial, even for promising research.
How Far Along Is the Research, and What Do the Animal Studies Show?
The research team is currently in the preclinical testing phase, conducting studies on genetically modified mice that carry the same mutations responsible for Alzheimer’s in humans. This is a critical stage because it allows researchers to test whether the treatment actually addresses the disease mechanism in living systems before any human exposure. The team is using blood tests and following FDA-required protocols during these mouse studies, establishing the safety and efficacy data necessary to justify moving to human clinical trials. The publication of results in *Alzheimer’s & Dementia* is significant because it indicates the research has met the peer-review standards of the field’s leading journal.
However, it’s important to note that successful mouse studies—even published ones—don’t guarantee human efficacy. Many treatments that work in mice fail in humans due to differences in metabolism, brain biology, and disease complexity. The FDA protocols being followed now exist precisely because of this historical gap. Patients and families reading about this research should understand that publication and patent status are positive indicators, but they don’t mean treatment is imminent.
What Role Do Patents and Intellectual Property Play in This Development?
UNC Pembroke’s research team holds a issued patent on Alzheimer’s-related technology from 2022, with a second patent currently pending for their more recent developments. Patents serve two critical functions in drug development: they protect the intellectual property so the lab can commercialize the work, and they document the technical details in a way that establishes priority and prevents others from copying the approach. In this case, the issued patent and pending patent indicate the lab has developed patentable innovations beyond just using ginseng—likely the specific formulations, delivery mechanisms, or combinations of compounds. Dr.
Bahr is launching a spin-off company to license and commercialize this intellectual property. This is common in academic research: university labs develop promising science, and then commercial entities are formed to handle manufacturing, regulatory approval, and market distribution. The spin-off model allows university researchers to remain focused on basic science while entrepreneurs and industry professionals handle the business side. However, the existence of a spin-off company also means financial success depends on commercial viability—the treatment will need to be both effective and economically feasible to manufacture and market at a price point patients and insurers will accept.
What Does the NCInnovation Grant Mean for Development Timeline?
Dr. Bahr’s lab received funding from North Carolina’s NCInnovation program, which supports commercialization of university research. This is not basic research funding—it’s specifically designated to help promising academic discoveries move toward the marketplace. NCInnovation grants accelerate development by providing resources for preclinical studies, patent filing, regulatory pathway planning, and early commercialization activities.
The grant recognition also signals that state-level organizations believe this research has genuine commercial potential. Even with grant funding and institutional support, timelines for Alzheimer’s drug development are measured in years, not months. A typical pathway from where this research currently stands would involve completing preclinical studies (1-2 years), filing an Investigational New Drug (IND) application with the FDA (several months to review), conducting Phase 1 safety trials in healthy volunteers (1-2 years), then Phase 2 efficacy trials in Alzheimer’s patients (2-3 years), and finally Phase 3 larger-scale trials (2-3 years). This means realistic estimates for FDA approval would be 5-10 years from today, barring any major delays or setbacks. Patients and families evaluating this research should be cautious about overly optimistic timelines sometimes promoted in media coverage.
What Are the Limitations and Uncertainties in This Research?
The biggest limitation is that synaptic resiliency, while an important factor in cognitive aging, may not be the complete Alzheimer’s disease mechanism. Alzheimer’s involves multiple pathological processes: amyloid accumulation, tau tangles, inflammation, mitochondrial dysfunction, and neuronal loss. A treatment that improves synaptic function might slow cognitive decline without stopping the disease entirely. This doesn’t mean the research lacks value—slowing Alzheimer’s progression by even a few years would be medically significant—but it’s worth understanding that “Alzheimer’s treatment” could mean different things: cure, halt, or slow-down.
Additionally, American ginseng’s effects are well-documented in traditional medicine and some clinical research, but its bioavailability and concentration in the brain matter enormously. Just because ginseng contains compounds that support synaptic function in test tubes doesn’t guarantee those compounds reach the brain in sufficient quantities when given as a pill or infusion. The lab’s formulation work addresses this, but it remains an area where preclinical success doesn’t automatically predict clinical success. Regulatory approval will require careful documentation that the treatment achieves its intended mechanism at safe doses.
How Does American Ginseng Compare to Other Alzheimer’s Research Approaches?
American ginseng is one of many botanical compounds being studied for Alzheimer’s support. Other researchers investigate turmeric (curcumin), blueberry extracts, green tea compounds, and various herbal formulations. What sets the UNC Pembroke approach apart isn’t the ginseng itself—it’s the mechanism (synaptic resiliency), the formal testing in genetically relevant mouse models, the patent protection, and the institutional and grant support moving it toward commercialization. Most botanical Alzheimer’s research remains in preliminary stages; the UNC work has advanced further into the pipeline.
The spin-off company model also matters. Many promising botanical compounds never reach market because there’s no commercial incentive to fund expensive clinical trials for something that can’t be patented (since ginseng is a natural product). By developing patentable formulations and small-molecule derivatives, Dr. Bahr’s lab has created intellectual property that a company can invest in and protect, increasing the likelihood the research will actually reach patients rather than remaining an academic publication.
What Does This Research Mean for the Future of Alzheimer’s Treatment?
The UNC Pembroke research represents a growing trend: Alzheimer’s treatment development is diversifying beyond the amyloid hypothesis. For decades, almost all research focused on clearing amyloid plaques from the brain, and while some progress has been made, this single-target approach has limitations. Research like Dr.
Bahr’s, which targets synaptic function and brain resilience, reflects a more nuanced understanding of Alzheimer’s as a multi-pathway disease requiring multi-targeted solutions. If successful, a ginseng-based treatment or the small-molecule derivatives developed from it could offer several advantages: lower cost than some current treatments, potential oral dosing rather than infusions, use of a well-tolerated botanical ingredient, and a mechanism complementary to existing treatments. The next 5-10 years will determine whether this promise translates into clinical benefit. For patients and families currently managing Alzheimer’s disease, this research offers hope without immediate timeline—a reminder that while treatments in development are important, current management strategies and lifestyle modifications remain the proven interventions available today.
Conclusion
UNC Pembroke’s Alzheimer’s Disease Research Lab, led by Dr. Ben Bahr, is developing a treatment approach grounded in published research, patent protection, and active commercialization efforts. The work focuses on improving synaptic resiliency using American ginseng and small-molecule drug candidates, with preclinical testing underway in genetically relevant mouse models. The research has demonstrated sufficient promise to attract NCInnovation Grant funding and to motivate the launch of a spin-off company, positioning it more seriously than purely academic research.
Realistic expectations matter. This research is several years away from clinical trials and many more years from potential FDA approval. However, the combination of mechanism-based science, peer-reviewed publication, patent protection, and commercialization support indicates that if the treatment continues to show promise, it has better odds of reaching patients than most early-stage Alzheimer’s research. Patients, families, and caregivers should monitor this development while continuing to rely on proven strategies for cognitive health and Alzheimer’s management today.
